Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT00112502. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Study identification
- NCT ID
- NCT00112502
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 178 participants
Conditions and interventions
Interventions
- Celecoxib Drug
- Isotretinoin Drug
- Temozolomide Drug
- Thalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Oct 17, 2021
2005 – 2014
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hembree Mercy Cancer Center at St. Edward Mercy Medical Center | Fort Smith | Arkansas | 72913 | — |
| University of Texas MD Anderson Cancer Center at Orlando | Orlando | Florida | 32806-2134 | — |
| CCOP - Atlanta Regional | Atlanta | Georgia | 30342-1701 | — |
| CCOP - Central Illinois | Decatur | Illinois | 62526 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| CCOP - Grand Rapids | Grand Rapids | Michigan | 49503 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| CCOP - Kansas City | Kansas City | Missouri | 64131 | — |
| Cancer Research for the Ozarks | Springfield | Missouri | 65804 | — |
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210-1240 | — |
| CCOP - Upstate Carolina | Spartanburg | South Carolina | 29303 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00112502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00112502 live on ClinicalTrials.gov.